Topic: VALNEVA
18 results were found.
FDA accepts Valneva’s Chikungunya vaccine license application for priority review - February 20, 2023
Valneva makes U.S. regulatory submission for one-shot chikungunya vaccine - December 23, 2022
Valneva seeking partnership for next-gen COVID-19 vaccine - September 26, 2022
Valneva and IDT Biologika to end COVID vaccine drug substance manufacturing deal - September 19, 2022
EMA recommends Valneva’s COVID-19 vaccine for authorisation in EU - June 24, 2022
Pfizer to buy 8.1% stake in vaccines company Valneva - June 20, 2022
Valneva provides update on European inactivated, whole-virus COVID-19 vaccine program VLA2001 - June 11, 2022
Valneva informed by EU it plans to drop COVID vaccine deal, gets emergency use nod in UAE - May 16, 2022
Albumedix and Valneva's collaboration to include newly approved inactivated COVID-19 vaccine - April 15, 2022
UK's Medicines and Healthcare products Regulatory Agency approved Valneva COVID-19 vaccine - April 14, 2022
Valneva receives emergency use authorization from Bahrain for its inactivated COVID-19 vaccine VLA2001 - March 2, 2022
Valneva advances booster phase of Cov-Compare trial of its inactivated COVID-19 vaccine candidate - January 26, 2022
EMA starts rolling review of Valneva’s COVID-19 vaccine - December 2, 2021
Commission approves contract with Valneva to secure a new potential vaccine - November 11, 2021
Valneva says its COVID-19 vaccine triggers significantly stronger immune response - October 19, 2021
UK terminates COVID-19 vaccine supply agreement with Valneva - September 13, 2021
UK orders 100mn doses of French Valneva COVID-19 vaccine candidate - February 1, 2021
UK agrees joint investment with Valneva to boost vaccine production - August 5, 2020